SCHEMBL2278166

SCHEMBL2278166

CCCNC(C)=CC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
MMP9 P14780 1/20 0.40
KDM4C Q9H3R0 1/20 0.39
EPHX1 P07099 2/20 0.39
PAOX Q6QHF9 1/20 0.38
MCL1 Q07820 1/20 0.38
CNR1 P21554 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 6/20 0.33
KMT2A Q03164 2/20 0.33
ATM Q13315 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
EPHX2 P34913 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12490812 0.87 EPHX1 (0.47) MMP2EPHX1CNR1EPHX2
SCHEMBL9179050 0.87 EPHX1 (0.47) MMP2EPHX1CNR1EPHX2
SCHEMBL9434817 0.85 EPHX1 (0.52) EPHX1EPHX2
SCHEMBL11748394 0.84 MMP1 (0.41) MMP1MMP2MMP3MMP9KDM4C
SCHEMBL11748399 0.84 MMP1 (0.41) MMP1MMP2MMP3MMP9KDM4C
SCHEMBL5701154 0.84 EPHX1 (0.55) EPHX1EPHX2
SCHEMBL9434500 0.84 EPHX1 (0.55) EPHX1EPHX2
SCHEMBL5701151 0.84 EPHX1 (0.55) EPHX1EPHX2
SCHEMBL9433763 0.84 EPHX1 (0.55) EPHX1EPHX2
SCHEMBL9433605 0.84 EPHX1 (0.55) EPHX1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989633-B2 4-Chromenonyl-1,4-dihydropyridines and their use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-02 US disclosed
US-20100022484-A1 4-Chromenonyl-1,4-dihydropyridines and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-28 US disclosed
EP-0371492-B1 Process for the preparation of 1,4-dihydropyridine derivatives NISSHIN FLOUR MILLING CO (JP) 1995-06-21 EP disclosed
US-5276150-A Vasodilators, anticoagulants, calcium channel blockers FUJIREBIO INC. (JP) 1994-01-04 US disclosed
EP-0184841-B1 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME NISSHIN FLOUR MILLING CO., LTD. (JP) 1992-11-11 EP disclosed
EP-0461264-A1 ETHYNYLPHENYL DERIVATIVE, PRODUCTION THEREOF, AND REMEDY FOR DISEASES OF CIRCULATORY ORGANS CONTAINING THE SAME AS ACTIVE INGREDIENT KAKEN PHARMACEUTICAL CO., LTD. (JP) 1991-12-18 EP disclosed
EP-0400660-A1 1,4-dihydropyridine derivatives FUJIREBIO INC. (JP) 1990-12-05 EP disclosed
EP-0371492-A2 Process for the preparation of 1,4-dihydropyridine derivatives NISSHIN FLOUR MILLING CO., LTD. (JP) 1990-06-06 EP disclosed
US-4757071-A 1,4-dihydropyridine derivatives, and pharmaceutical compositions containing same, useful for treating cardiovascular diseases NISSHIN FLOUR MILLING CO., LTD. (JP) 1988-07-12 US disclosed
EP-0184841-A2 1,4-Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions containing same NISSHIN FLOUR MILLING CO., LTD. (JP) 1986-06-18 EP disclosed
US-4558058-A HYPOTENSIVE AGENTS CASSELLA AKTIENGESELLSCHAFT (DE) 1985-12-10 US disclosed
US-4525478-A Certain 4-aryl-1,4-dihydro-3,5-pyridinedicarboxylates having vasodilating and anti-hypertensive properties FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-06-25 US disclosed
US-4370334-A VASODILATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-25 US disclosed
US-4338322-A 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-07-06 US disclosed
US-4284634-A HYPOTENSIVE VASODILATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022484-A1 4-Chromenonyl-1,4-dihydropyridines and their use RYR1, RYR2, CACNA1S MMP1 4330/4885MMP2 3538/4885MMP3 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.